We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Stevens–Johnson syndrome after treatment with STI571: a case report.
- Authors
Hsiao, Liang-Tsai; Chung, Hung-Ming; Lin, Jen-Tsun; Chiou, Tzeon-Jye; Liu, Jin-Hwang; Fan, Frank S; Wang, Wei-Shu; Yen, Chueh-Chuan; Chen, Po-Min
- Abstract
Summary. Between seven and 21% of patients treated with the specific tyrosine kinase inhibitor STI571 have been reported to develop mild-to-moderate severity of adverse cutaneous reactions. We report a patient in the blast crisis phase of chronic myeloid leukaemia who developed a life-threatening cutaneous reaction, Stevens–Johnson syndrome, following 1 week of STI571 therapy. This report may serve to remind the clinician about the possible severe cutaneous side-effects of STI571 before instituting more extensive clinical application of this agent in the future.
- Subjects
MYELOID leukemia; SYNDROMES; PROTEIN-tyrosine kinase inhibitors
- Publication
British Journal of Haematology, 2002, Vol 117, Issue 3, p620
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1046/j.1365-2141.2002.03499.x